Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985861 | 0.85 | HMOX2 (0.35) | HRH4TBXAS1MMP2 | |
| SCHEMBL6981588 | 0.80 | CAPN1 (0.40) | CTSK | |
| SCHEMBL7816001 | 0.78 | CTSK (0.41) | CYP19A1CYP11B1CYP11B2HRH4CTSS | |
| SCHEMBL6980337 | 0.78 | ADAM17 (0.33) | CYP19A1AGTR2 | |
| SCHEMBL6981901 | 0.77 | HRH4 (0.39) | CYP19A1CYP11B1CYP11B2HRH4CTSS | |
| SCHEMBL6982695 | 0.77 | CTSS (0.33) | CTSSCTSKAGTR2 | |
| SCHEMBL6986296 | 0.73 | ADAM17 (0.44) | CYP19A1CYP11B1CYP11B2HRH4CTSS | |
| SCHEMBL6988970 | 0.71 | ADAM17 (0.36) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL6937767 | 0.70 | ADAM17 (0.39) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL6986412 | 0.70 | ADAM17 (0.39) | MMP1MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089964-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |
| EP-1089964-A1 | HYDRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000465-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-06 | — | — | WO | disclosed |